<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0379-3982</journal-id>
<journal-title><![CDATA[Revista Tecnología en Marcha]]></journal-title>
<abbrev-journal-title><![CDATA[Tecnología en Marcha]]></abbrev-journal-title>
<issn>0379-3982</issn>
<publisher>
<publisher-name><![CDATA[Instituto Tecnológico de Costa Rica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0379-39822021000100025</article-id>
<article-id pub-id-type="doi">10.18845/tm.v34i1.4654</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Anticuerpos monoclonales y el tratamiento del lupus eritematoso sistémico]]></article-title>
<article-title xml:lang="en"><![CDATA[Monoclonal antibodies and the treatment of systemic lupus erythematosus]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chavarría-Tapia]]></surname>
<given-names><![CDATA[Alex]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández-Corella]]></surname>
<given-names><![CDATA[Ariana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marenco-Acosta]]></surname>
<given-names><![CDATA[Henry]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Shen Zhou]]></surname>
<given-names><![CDATA[Yorleny]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ugalde-Zumbado]]></surname>
<given-names><![CDATA[Malcolm]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mora-Román]]></surname>
<given-names><![CDATA[Juan José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Universidad de Costa Rica Departamento de Farmacia Industrial Facultad de Farmacia]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2021</year>
</pub-date>
<volume>34</volume>
<numero>1</numero>
<fpage>25</fpage>
<lpage>39</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S0379-39822021000100025&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S0379-39822021000100025&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S0379-39822021000100025&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El lupus eritematoso sistémico es una enfermedad autoinmune crónica, que implica la producción de ciertos anticuerpos en todo el cuerpo y la consecuente inflamación de tejidos conjuntivos, así como afecciones cutáneas, hematológicas y cardiovasculares, entre otras. Se ha postulado su procedencia genética, ambiental o inmunológica, incluso de factores hormonales, pero en realidad su etiología es desconocida. El tratamiento convencional se basa en la severidad de sus manifestaciones clínicas. La primera línea de tratamiento es la administración de fármacos antipalúdicos, inmunosupresores, glucocorticoides y metotrexato. Por muchos años, estos han sido de ayuda para los pacientes que sufren esta enfermedad. Lamentablemente, son muy poco selectivos, por lo que causan graves efectos adversos. Ante esta situación, se ha probado el uso de terapias biológicas, las cuales presentan la ventaja de ser más específicas. Una de estas son los anticuerpos monoclonales, como el belimumab, que han disminuido los riesgos de brotes y han mejorado la actividad serológica de los pacientes. Como en el caso del lupus eritematoso sistémico, cada día se está ampliando la investigación enfocada en terapia biológica para el tratamiento de distintas enfermedades autoinmunes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Systemic lupus erythematosus is a chronic autoimmune disease that involves the production of certain antibodies throughout the body and the consequent inflammation of connective tissue, as well as skin, hematological, and cardiovascular conditions, among others. Postulates about its origin vary from a genetic to an environmental, an immunological or a hormonal one, but actually its etiology is unknown. Conventional treatment is based on the severity of its clinical manifestations. The first line of treatment is the administration of antimalarial drugs, immunosuppressants, glucocorticoids, and methotrexate. For many years, all of these medications have given some relief to patients suffering from this disease. Unfortunately, they are not very selective, reason why they cause serious adverse effects to the patients. Given this situation, the use of biological therapies has been sought; these have the advantage of being more specific. One of them are the monoclonal antibodies, such as belimumab, which have reduced the risk of flares and have improved the serological activity of patients. Therefore, research focused on biological therapy for the treatment of different autoimmune diseases such as systemic lupus erythematosus is being expanded every day.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Lupus eritematoso sistémico]]></kwd>
<kwd lng="es"><![CDATA[cloroquina]]></kwd>
<kwd lng="es"><![CDATA[hidroxicloroquina]]></kwd>
<kwd lng="es"><![CDATA[inmunosupresores]]></kwd>
<kwd lng="es"><![CDATA[glucocorticoides]]></kwd>
<kwd lng="es"><![CDATA[metotrexato]]></kwd>
<kwd lng="es"><![CDATA[terapia biológica]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos monoclonales]]></kwd>
<kwd lng="en"><![CDATA[Systemic lupus erythematosus]]></kwd>
<kwd lng="en"><![CDATA[chloroquine]]></kwd>
<kwd lng="en"><![CDATA[hydroxychloroquine]]></kwd>
<kwd lng="en"><![CDATA[immunosuppressants]]></kwd>
<kwd lng="en"><![CDATA[glucocorticoids]]></kwd>
<kwd lng="en"><![CDATA[methotrexate]]></kwd>
<kwd lng="en"><![CDATA[biological therapy]]></kwd>
<kwd lng="en"><![CDATA[monoclonal antibodies]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>(1)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohd Shahrir]]></surname>
<given-names><![CDATA[M. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Abdul Halim]]></surname>
<given-names><![CDATA[A. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Soehardy]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Norella Kong]]></surname>
<given-names><![CDATA[C. T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical experience in using CD20 monoclonal antibody in treating severe systemic lupus erythematosus]]></article-title>
<source><![CDATA[APLAR Journal of Rheumatology]]></source>
<year>2007</year>
<page-range>112-6</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>(2)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[R. I. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Scheinberg]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Queiroz]]></surname>
<given-names><![CDATA[M. Y. C. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Brito]]></surname>
<given-names><![CDATA[D. C. S. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[M. F. B. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Giovelli]]></surname>
<given-names><![CDATA[R. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of rituximab as a treatment for systemic lupus erythematosus: Retrospective review]]></article-title>
<source><![CDATA[Einstein]]></source>
<year>2014</year>
<numero>1</numero>
<issue>1</issue>
<page-range>36-41</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>(3)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[H. M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Abohamad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Elfishawi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hegazy]]></surname>
<given-names><![CDATA[M. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Vijaykumar]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: A critical review with focus on safety and satisfaction]]></article-title>
<source><![CDATA[Patient Preference and Adherence]]></source>
<year>2018</year>
<page-range>2475-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>(4)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Puerta]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Cervera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lupus eritematoso sistémico]]></article-title>
<source><![CDATA[Medicina &amp; Laboratorio]]></source>
<year>2008</year>
<numero>5-6</numero>
<issue>5-6</issue>
<page-range>211-23</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>(5)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Specchia]]></surname>
<given-names><![CDATA[M. L]]></given-names>
</name>
<name>
<surname><![CDATA[de Waure]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gualano]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Doria]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Turchetti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pippo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health technology assessment of belimumab: A new monoclonal antibody for the treatment of systemic lupus erythematosus]]></article-title>
<source><![CDATA[BioMed Research International]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>(6)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakthiswary]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Suresh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2014</year>
<numero>3</numero>
<issue>3</issue>
<page-range>225-35</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>(7)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villalobos Zúñiga]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedades infecciosas en pacientes con lupus eritematoso sistémico en el Hospital Calderón Guardia: caracterización, incidencia, profilaxis y factores asociados]]></article-title>
<source><![CDATA[Revista Clínica de la Escuela de Medicina UCR]]></source>
<year>2012</year>
<numero>6</numero>
<issue>6</issue>
<page-range>21</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>(8)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaper]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[van Timmeren]]></surname>
<given-names><![CDATA[M. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Petersen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Horst]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bijl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Limburg]]></surname>
<given-names><![CDATA[P. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment with antiHMGB1 monoclonal antibody does not affect lupus nephritis in MRL/Ipr mice]]></article-title>
<source><![CDATA[Molecular Medicine]]></source>
<year>2016</year>
<page-range>12-21</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>(9)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hui-Yuen]]></surname>
<given-names><![CDATA[J. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[S. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Askanase]]></surname>
<given-names><![CDATA[A. D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2016</year>
<numero>10</numero>
<issue>10</issue>
<page-range>1086-96</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>(10)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flores-Ramírez]]></surname>
<given-names><![CDATA[J. F.]]></given-names>
</name>
<name>
<surname><![CDATA[García-Bernal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Morales-León]]></surname>
<given-names><![CDATA[E. U.]]></given-names>
</name>
<name>
<surname><![CDATA[Islas-Martínez]]></surname>
<given-names><![CDATA[C. U.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Usos de anticuerpos monoclonales en medicina]]></article-title>
<source><![CDATA[TEXEPI, Boletín Científico de la Escuela Superior Tepeji del Río]]></source>
<year>2019</year>
<page-range>25-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>(11)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zurita-Gavilanes]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Costa-Valarezo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rituximab in lupus nephritis: A non-systematic review]]></article-title>
<source><![CDATA[Reumatología Clínica]]></source>
<year>2016</year>
<numero>4</numero>
<issue>4</issue>
<page-range>210-5</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>(12)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Enberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Goity]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Villalón]]></surname>
<given-names><![CDATA[M. V.]]></given-names>
</name>
<name>
<surname><![CDATA[Zamorano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infecciones en pacientes con lupus eritematoso sistémico]]></article-title>
<source><![CDATA[Revista Médica de Chile]]></source>
<year>2009</year>
<numero>10</numero>
<issue>10</issue>
<page-range>1367-74</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>(13)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toche]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Visión panorámica del sistema inmune]]></article-title>
<source><![CDATA[Revista Médica Clínica Las Condes]]></source>
<year>2012</year>
<numero>4</numero>
<issue>4</issue>
<page-range>446-57</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>(14)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filella]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ballesta]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estructura y función de las citocinas]]></article-title>
<source><![CDATA[Medicina Integral]]></source>
<year>2002</year>
<numero>2</numero>
<issue>2</issue>
<page-range>63-71</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>(15)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barahona-López]]></surname>
<given-names><![CDATA[D. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Sierra]]></surname>
<given-names><![CDATA[L. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Matute-Martínez]]></surname>
<given-names><![CDATA[C. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Barahona-López]]></surname>
<given-names><![CDATA[I. A.]]></given-names>
</name>
<name>
<surname><![CDATA[PerdomoVaquero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Erazo-Trimarchi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hospitalización en lupus eritematoso sistémico: causas, actividad lúpica y evolución]]></article-title>
<source><![CDATA[Medicina Interna de México]]></source>
<year>2017</year>
<numero>6</numero>
<issue>6</issue>
<page-range>730-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>(16)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esquivel-Pedraza]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Cuevas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Jiménez]]></surname>
<given-names><![CDATA[Y. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Cherit]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez-Flores]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lesiones de la mucosa bucal por administración de metotrexato en pacientes con artritis reumatoide]]></article-title>
<source><![CDATA[Dermatología, Revista Méxicana]]></source>
<year>2017</year>
<volume>61</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>492-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>(17)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alfonso-Valdés]]></surname>
<given-names><![CDATA[M. E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunopatogenia de la psoriasis: impacto en las manifestaciones clínicas y el tratamiento de la enfermedad]]></article-title>
<source><![CDATA[Revista Cubana Hematología, Inmunología y Hemoterapia]]></source>
<year>2012</year>
<numero>4</numero>
<issue>4</issue>
<page-range>357-73</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>(18)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Collazo]]></surname>
<given-names><![CDATA[A. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Mena]]></surname>
<given-names><![CDATA[A. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrusco-Ontiveros]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Poletti-Vázquez]]></surname>
<given-names><![CDATA[E. D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estomatitis por metotrexato y sus efectos orales a bajas dosis]]></article-title>
<source><![CDATA[Dermatología, Revista Mexicana]]></source>
<year>2014</year>
<page-range>458-64</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>(19)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[S. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Furst]]></surname>
<given-names><![CDATA[D. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Bao]]></surname>
<given-names><![CDATA[C. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A 1-year study of two doses of steroid in combination with methotrexate and chloroquine in the treatment of patients with mild and moderate systemic lupus erythematosus]]></article-title>
<source><![CDATA[APLAR Journal of Rheumatology]]></source>
<year>2006</year>
<page-range>392-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>(20)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Islam]]></surname>
<given-names><![CDATA[M. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Hossain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haq]]></surname>
<given-names><![CDATA[S. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[M. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Ten Klooster]]></surname>
<given-names><![CDATA[P. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rasker]]></surname>
<given-names><![CDATA[J. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus]]></article-title>
<source><![CDATA[International Journal of Rheumatic Diseases]]></source>
<year>2012</year>
<numero>1</numero>
<issue>1</issue>
<page-range>62</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>(21)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brochet]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Deloire]]></surname>
<given-names><![CDATA[M. S. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Loock]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Baschet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Debouverie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Double-blind controlled randomized trial of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis]]></article-title>
<source><![CDATA[PLoS ONE,]]></source>
<year>2017</year>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>(22)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Karim]]></surname>
<given-names><![CDATA[D. R. G.]]></given-names>
</name>
<name>
<surname><![CDATA[El-Amrawi]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclophosphamide hepatotoxicity: The role of 4-hydroxynonenal and cytochrome C oxidase and the possible protective effect of Ganoderma lucidum extract]]></article-title>
<source><![CDATA[Slovenian Veterinary Research]]></source>
<year>2019</year>
<numero>^s22</numero>
<issue>^s22</issue>
<supplement>22</supplement>
<page-range>15-23</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>(23)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lian]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of thiopurine methyltransferase status with azathioprine side effects in Chinese patients with systemic lupus erythematosus,]]></article-title>
<source><![CDATA[Clinical Rheumatology]]></source>
<year>2014</year>
<numero>4</numero>
<issue>4</issue>
<page-range>499-503</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>(24)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borazan]]></surname>
<given-names><![CDATA[N. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Furst]]></surname>
<given-names><![CDATA[D. E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fármacos antiinflamatorios no esteroideos, antirreumáticos modificadores de la enfermedad, analgésicos no opioides y fármacos usados en la gota]]></article-title>
<source><![CDATA[Farmacología Básica y Clínica]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>(25)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2019</year>
<numero>1</numero>
<issue>1</issue>
<page-range>129-32</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>(26)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Graña]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Goñi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Irastorza]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas]]></article-title>
<source><![CDATA[Revista Médica de Chile]]></source>
<year>2016</year>
<numero>2</numero>
<issue>2</issue>
<page-range>232-40</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>(27)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gatto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Iaccarino]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Doria]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New therapeutic strategies in systemic lupus erythematosus management]]></article-title>
<source><![CDATA[Nature Reviews Rheumatology]]></source>
<year>2019</year>
<numero>1</numero>
<issue>1</issue>
<page-range>30-48</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>(28)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fanouriakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pamfil]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sidiropoulos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Damian]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Flestea]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gusetu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A retrospective, observational two-centre study]]></article-title>
<source><![CDATA[Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus]]></source>
<year>2016</year>
<volume>25</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>627-36</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>(29)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Igarashi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Igarashi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Itoh]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous Cyclophosphamide Pulse Therapy in Japanese Children with Systemic Lupus Erythematosus]]></article-title>
<source><![CDATA[Journal of Nippon Medical School,]]></source>
<year>2013</year>
<numero>5</numero>
<issue>5</issue>
<page-range>396-400</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>(30)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chico Capote]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Estévez del Toro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gálvez Vallejo]]></surname>
<given-names><![CDATA[J. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Chía Proenza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chong López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glomerulopatía colapsante en lupus eritematoso sistémico con respuesta positiva a tratamiento con mofetil micofenolato]]></article-title>
<source><![CDATA[Revista Cubana de Medicina]]></source>
<year>2018</year>
<numero>2</numero>
<issue>2</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>(31)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krensky]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Azzi]]></surname>
<given-names><![CDATA[J. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Hafler]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunosuppressants and Tolerogens]]></article-title>
<source><![CDATA[Goodman &amp; Gilman&#8217;s. The Pharmacological Basis of Therapeutics]]></source>
<year>2018</year>
<edition>13th</edition>
</nlm-citation>
</ref>
<ref id="B32">
<label>(32)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vera-Lastra]]></surname>
<given-names><![CDATA[O. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Olvera-Acevedo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Carillo-González]]></surname>
<given-names><![CDATA[A. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Ángeles-Garay]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efecto de pravastatina más ezetimibe en el grosor intimamedia carotídea en pacientes con lupus eritematoso]]></article-title>
<source><![CDATA[Revista Médica del Instituto Mexicano del Seguro Social]]></source>
<year>2015</year>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S74-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>(33)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kabadi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yeaw]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bacani]]></surname>
<given-names><![CDATA[A K.]]></given-names>
</name>
<name>
<surname><![CDATA[Tafesse]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bos]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Karkare]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus,]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2018</year>
<numero>11</numero>
<issue>11</issue>
<page-range>1799-809</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>(34)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Englund]]></surname>
<given-names><![CDATA[J. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Kerns]]></surname>
<given-names><![CDATA[W. P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beta Bloqueadores]]></article-title>
<source><![CDATA[Medicina de Urgencias]]></source>
<year>2018</year>
<volume>8</volume>
<publisher-loc><![CDATA[Estados Unidos ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill Education]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B35">
<label>(35)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bienias]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ciurzy&#324;ski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chrzanowska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dudzik-Niewiadomska]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Irzyk]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Oleszek]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Attenuated post-exercise heart rate recovery in patients with systemic lupus erythematosus: the role of disease severity and beta-blocker treatment,]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2018</year>
<numero>2</numero>
<issue>2</issue>
<page-range>217-24</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>(36)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antibodies]]></article-title>
<source><![CDATA[Review of Medical Microbiology and Immunology]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Estados Unidos ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B37">
<label>(37)</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sadava]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Heller]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Orians]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Purves]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Hillis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Vida: La Ciencia de la Biología]]></source>
<year>2009</year>
<edition>8</edition>
</nlm-citation>
</ref>
<ref id="B38">
<label>(38)</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paniagua]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nistal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sesma]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-Uría]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fraile]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Anadón]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Madrid: McGraw-Hill/ Interamericana de España]]></source>
<year>2017</year>
<edition>4</edition>
</nlm-citation>
</ref>
<ref id="B39">
<label>(39)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magadán]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[González-Fernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Generación de anticuerpos monoclonales in vivo]]></article-title>
<source><![CDATA[Anticuerpos Monoclonales: Realidades y Perspectivas, L. Álvarez Vallina, Ed. Madrid: Editorial Complutense, S.A,]]></source>
<year>2004</year>
</nlm-citation>
</ref>
<ref id="B40">
<label>(40)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[N. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Téllez]]></surname>
<given-names><![CDATA[G. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Castaño]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpos monoclonales: desarrollo físico y perspectivas terapéuticas,]]></article-title>
<source><![CDATA[Infectio]]></source>
<year>2006</year>
<numero>3</numero>
<issue>3</issue>
<page-range>186-97</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>(41)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Calvo]]></surname>
<given-names><![CDATA[E. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpos monoclonales en el tratamiento de cáncer,]]></article-title>
<source><![CDATA[tesis, Universidad Complutense]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Madrid, España ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B42">
<label>(42)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laffleur]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pascal]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sirac]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cogné]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Production of human or humanized antibodies in mice,]]></article-title>
<source><![CDATA[Antibody Methods and Protocols. Methods in Molecular Biology (Methods and Protocols)]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B43">
<label>(43)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayrhofer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kunert]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives]]></article-title>
<source><![CDATA[Human Antibodies]]></source>
<year>2019</year>
<page-range>37</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>(44)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeoh]]></surname>
<given-names><![CDATA[S. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[S. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Ienberg]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in systemic lupus erythematosus,]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2018</year>
<numero>2</numero>
<issue>2</issue>
<page-range>84-92</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>(45)</label><nlm-citation citation-type="journal">
<collab>Food and Drug Administration</collab>
<article-title xml:lang=""><![CDATA[FDA approves first treatment for pediatric patients with lupus.]]></article-title>
<source><![CDATA[https://www.fda.gov/news-events/press-announcements/fda-approves-firsttreatment-pediatric-patients-lupus]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B46">
<label>(46)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hafeez]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Gan]]></surname>
<given-names><![CDATA[H. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases]]></article-title>
<source><![CDATA[Current Opinion in Pharmacology]]></source>
<year>2018</year>
<page-range>114-21</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>(47)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marcondes]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Scheinberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Belimumab in the treatment of systemic lupus erythematous: An evidence based review of its place in therapy]]></article-title>
<source><![CDATA[Autoimmunity Reviews]]></source>
<year>2018</year>
<numero>2</numero>
<issue>2</issue>
<page-range>103-7</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>(48)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarra]]></surname>
<given-names><![CDATA[S. V.]]></given-names>
</name>
<name>
<surname><![CDATA[Guzmán]]></surname>
<given-names><![CDATA[R. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Gallacher]]></surname>
<given-names><![CDATA[A. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[R. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Jimenez]]></surname>
<given-names><![CDATA[R. E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomized, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2011</year>
<numero>9767</numero>
<issue>9767</issue>
<page-range>721-31</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>(49)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Furie]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Petri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zamani]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Cervera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wallace]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Tegzová]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus]]></article-title>
<source><![CDATA[Arthritis &amp; Rheumatism]]></source>
<year>2011</year>
<numero>12</numero>
<issue>12</issue>
<page-range>3918-30</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>(50)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramsköld]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Parodis]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lakshmikanth]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sippl]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Khademi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[B cell alterations during BAFF inhibition with belimumab in SLE]]></article-title>
<source><![CDATA[EbioMedicine]]></source>
<year>2019</year>
<page-range>517-27</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>(51)</label><nlm-citation citation-type="journal">
<collab>National Institute for Health and Care Excellence</collab>
<article-title xml:lang=""><![CDATA[Belimumab for treating active autoantibody-positive systemic lupus erythematosus]]></article-title>
<source><![CDATA[National Institute for Health and Care Excellence, Londres, Technology Appraisal Guidance]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B52">
<label>(52)</label><nlm-citation citation-type="">
<collab>Ministerio de Salud</collab>
<source><![CDATA[Consulta de productos registrados en plataforma.]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B53">
<label>(53)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sopp]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cragg]]></surname>
<given-names><![CDATA[M. S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Deleting malignant B cells with second-generation anti-CD20 antibodies]]></article-title>
<source><![CDATA[Journal of Clinical Oncology]]></source>
<year>2018</year>
<numero>22</numero>
<issue>22</issue>
<page-range>2323-5</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>(54)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lei]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Muhammad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Obaidi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sebire]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[I. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Eleftheriou]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C &#948;]]></article-title>
<source><![CDATA[Pediatric Rheumatology]]></source>
<year>2018</year>
<numero>1</numero>
<issue>1</issue>
<page-range>61</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>(55)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bakshi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ismajli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New therapeutic avenues in SLE]]></article-title>
<source><![CDATA[Best Practice &amp; Research Clinical Rheumatology]]></source>
<year>2015</year>
<numero>6</numero>
<issue>6</issue>
<page-range>794-809</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>(56)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Speth]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hinze]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Häfner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination of ofatumumab and fresh frozen plasma in hypocomplementemic systemic lupus erythematosus: A case report]]></article-title>
<source><![CDATA[Lupus,]]></source>
<year>2018</year>
<numero>8</numero>
<issue>8</issue>
<page-range>1395-6</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>(57)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moschen]]></surname>
<given-names><![CDATA[A. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Tilg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Raine]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting,]]></article-title>
<source><![CDATA[Nature Reviews Gastroenterology &amp; Hepatology]]></source>
<year>2019</year>
<numero>3</numero>
<issue>3</issue>
<page-range>185-96</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Petri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic lupus erythematosus: Diagnosis and clinical management]]></article-title>
<source><![CDATA[Journal of Autoimmunity]]></source>
<year>2019</year>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>(59)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doody]]></surname>
<given-names><![CDATA[G. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Justement]]></surname>
<given-names><![CDATA[L. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Delibrias]]></surname>
<given-names><![CDATA[C. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[R. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[M. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP]]></article-title>
<source><![CDATA[Science]]></source>
<year>1995</year>
<numero>5221</numero>
<issue>5221</issue>
<page-range>242-4</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>(60)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic advances in the treatment of SLE]]></article-title>
<source><![CDATA[International Immunopharmacology]]></source>
<year>2019</year>
<page-range>218</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>(61)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drago Serrano]]></surname>
<given-names><![CDATA[M. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Sainz Espuñes]]></surname>
<given-names><![CDATA[T. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sistemas de expresión para proteínas terapéuticas recombinantes]]></article-title>
<source><![CDATA[Revista Mexicana de Ciencias Farmacéuticas]]></source>
<year>2006</year>
<numero>1</numero>
<issue>1</issue>
<page-range>38-44</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>(62)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrell]]></surname>
<given-names><![CDATA[R. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Jeppsson]]></surname>
<given-names><![CDATA[J. O.]]></given-names>
</name>
<name>
<surname><![CDATA[Laurell]]></surname>
<given-names><![CDATA[C. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[S. O.]]></given-names>
</name>
<name>
<surname><![CDATA[Owen]]></surname>
<given-names><![CDATA[M. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Vaughan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structure and variation of human &#945;1-antitrypsin]]></article-title>
<source><![CDATA[Nature]]></source>
<year>1982</year>
<numero>5872</numero>
<issue>5872</issue>
<page-range>329-34</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>(63)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elshikha]]></surname>
<given-names><![CDATA[A. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Abboud]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Akbar]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alpha 1 antitrypsin gene therapy extends the lifespan of lupus-prone mice,]]></article-title>
<source><![CDATA[Molecular Therapy Methods &amp; Clinical Development,]]></source>
<year>2018</year>
<page-range>131-42</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>(64)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[J Barbado]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tabera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
</name>
<name>
<surname><![CDATA[García-Sancho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2018</year>
<numero>13</numero>
<issue>13</issue>
<page-range>2161-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
